Review Article

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

Rupert Bauersachs, Olivia Wu, Neil Hawkins, Kevin Bowrin, Piotr Wojciechowski, Emilie Clay, and Maria Huelsebeck

1Klinikum Darmstadt GmbH, Darmstadt, Germany
2Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
3Bayer Plc, Reading, UK
4Creativ-Ceutical, Krakow, Poland
5Creativ-Ceutical, Paris, France
6Bayer AG, Berlin, Germany

Correspondence should be addressed to Rupert Bauersachs; bauersachs@em.uni-frankfurt.de

Received 19 May 2021; Accepted 3 August 2021; Published 24 August 2021

Background. The guidelines on antithrombotic treatment in patients with symptomatic peripheral artery disease (PAD) undergoing peripheral revascularization of the lower extremities were developed based on heterogeneous trials, assessing various dose regimens and recruiting patients who were subjected to different revascularization procedures. Objective. To compare efficacy and safety of treatments used in patients with PAD undergoing peripheral revascularization accounting for between-trial heterogeneity and large dispersion of the quality of evidence. Methods. A systematic literature review of randomised controlled trials (RCTs) recruiting adult patients with PAD receiving antithrombotics was conducted until January 2020. Hazard ratios (HR) were pooled using Bayesian network meta-analysis. The estimated between-treatment effects were presented as HR together with 95% credible intervals. The base case analysis included studies recruiting patients following recent peripheral revascularization, who received treatment regimens administered within the recommended therapeutic window, while a sensitivity scenario included all identified trials. Results. Thirteen RCTs were identified (8 RCTs enrolled patients following peripheral revascularization and 5 RCTs regardless of the previous revascularization). Five trials, recruiting an overall of 8349 patients, were considered for the base case analysis. Of those, 6564 patients were recruited in the VOYAGER PAD trial comparing rivaroxaban plus aspirin (RIV plus ASA) versus ASA. RIV plus ASA was associated with a lower risk of repeated peripheral revascularization versus ASA monotherapy (HR = 0.88 [0.79, 0.99]), however having a trend towards an increased rate of major bleeding (HR = 1.43 [0.98, 2.11]). There was no evidence for differences between RIV plus ASA and dual antiplatelet therapy and vitamin K antagonists plus ASA. Similar results were observed in sensitivity analyses. Conclusions. RIV plus ASA is associated with reduced risk of revascularization compared with ASA monotherapy, but the evidence for other comparators, in particular antiplatelet regimens, was insufficient to guide treatment decisions and highlights the challenge in establishing the magnitude of comparative efficacy using existing RCTs.
1. Introduction

Peripheral artery disease (PAD) is a common cardiovascular (CV) system disease with the global prevalence exceeding 200 million people and incidence of about 11 million in 2017 [1, 2]. Progressive atherosclerosis causes stenosis or occlusion of peripheral arteries. Depending on the location and severity of the stenosis, the disease is asymptomatic or symptomatic with intermittent claudication (IC) or atypical leg pain, critical limb ischemia (CLI), and acute limb ischemia (ALI) as typical signs [3–6]. CLI leads to chronic hypoperfusion resulting in a substantial increase in the risk of limb loss [7–9]. For this reason, patients with CLI or the occurrence of lifestyle-limiting symptoms classified as being grade IIb according to the Fontaine classification may require revascularization of the lower extremity arteries [10, 11]. Revascularization immediately improves quality of life in PAD patients and improves long-term survival [12], although it is associated with a postprocedural increase of vascular risk [13].

The clinical trials on the antithrombotic medication differ noticeably in terms of quality and sample size, with limited evidence for the efficacy and safety of antiplatelet medication used in patients who have undergone revascularization, in particular for those after recent endovascular procedures [4]. Due to this reason, the recommendations of practice guidelines were often developed based on low-quality evidence [4]. A single antiplatelet therapy (SAPT) with acetylsalicylic acid (ASA) or clopidogrel (CLO) alone is recommended for all patients with symptomatic PAD who have undergone revascularization to reduce the risk of atherothrombotic events (Class I with level of evidence C). Dual antiplatelet therapy (DAPT), consisting of low doses of ASA in combination with a P2Y12 receptor antagonist, is recommended for at least one month for patients following endovascular procedures (Class IIa with level of evidence C). DAPT with ASA plus CLO for at least 1 month can be considered in patients undergoing bypass surgery with a prosthetic graft (Class IIb with level of evidence B) [4].

Despite existing guidelines, a comparison of treatments for PAD patients after peripheral revascularization encounters heterogeneity of definitions, revascularization, venous thromboembolism (VTE), and hospitalization. Major bleeding (MB) was considered as a safety outcome; however, the definitions of this event varied across studies (Supplementary Table 7). Therefore, the comparison regarding major bleeding needs to be interpreted with caution.

2. Material and Methods

2.1. Systematic Literature Review. A systematic literature review (SLR) was conducted to identify randomised controlled trials (RCTs) on adult patients with acute symptomatic PAD, presenting the clinical evidence for the following therapeutic options: RIV plus ASA, CLO plus ASA, ASA monotherapy, CLO monotherapy, vitamin K antagonists (VKAs) with or without ASA or CLO, and a placebo. The search was conducted in January 2020 in MEDLINE, MEDLINE In-Process, EMBASE, and CENTRAL. No timeframe and geographical scope restrictions were imposed; however, for conferences/congresses searches, only records issued from 2015 on were considered. Inclusion criteria are summarised in Table 1.

The selection of RCTs was conducted by 2 analysts working independently, and any disagreements between the 2 analysts were resolved by a third analyst. Data from studies meeting all inclusion criteria were extracted by one analyst; its quality was thoroughly checked by the second analyst. The risk of bias was assessed for each study using the tool developed by the Cochrane Collaboration [15].

2.2. Additional Criteria for Inclusion in the Network Meta-Analysis. The intention of this analysis was to compare the RIV plus ASA regimen with treatments recommended by the current clinical practice guidelines to treat patients with PAD after revascularization. We considered all RCTs assessing antiplatelet therapies or anticoagulant treatment enrolling patients with PAD of lower extremity with and without a history of recent revascularization to increase the power of this NMA [4–6]. Based on clinical practice guidelines, the following therapies were considered as comparators for RIV plus ASA: ASA monotherapy, CLO monotherapy, CLO in combination with ASA, VKA monotherapy, and VKA plus ASA [4].

Treatments were compared regarding clinically relevant outcomes reported across analysed studies [14]. Efficacy outcomes included IS, any stroke, MI, CV death, coronary heart death, all-cause death, major amputations (between-trial heterogeneity of definition), revascularization, venous thromboembolism (VTE), and hospitalization. Major bleeding (MB) was considered as a safety outcome; however, the definitions of this event varied across studies (Supplementary Table 7). Therefore, the comparison regarding major bleeding needs to be interpreted with caution.

2.3. Data Synthesis. Two trials assessing RIV plus ASA in patients with PAD were identified through the SLR [14, 16]. Both compared a combination of RIV plus ASA versus ASA alone. There are no studies comparing efficacy and safety of RIV-based treatment to other therapies mentioned in the clinical guidelines. In 11 RCTs (BOA [17], CAPRIE [18], CASPAR [19], Cassar 2005 [20], CHARISMA [21],
An NMA in Bayesian framework was used to compare RIV plus ASA versus other treatments [26]. The NMA is an extension of traditional pairwise meta-analysis which uses Markov chain Monte Carlo sampling to compare different treatments assessed in different studies, if they form a connected network of evidence and allowing an indirect-treatment comparison using an NMA.

An NMA in Bayesian framework was used to compare RIV plus ASA versus other treatments [26]. The NMA is an extension of traditional pairwise meta-analysis which uses Markov chain Monte Carlo sampling to compare different treatments assessed in different studies, if they form a connected network of evidence.

The model inputs are natural logarithms of hazard ratio (log(HR)) for between-treatment comparison and the corresponding SE(log(HR)). When respective trials reported estimates calculated after several interim analyses, only final estimates corresponding to the longest available follow-up were included for the NMA. Neither of the included trials reported information suggesting violation of proportionality of hazards. For studies not reporting HRs, they were estimated by fitting the exponential survival curve to the reported number of events.

Three chains were initiated with noninformative priors and run in parallel for each analysis. The convergence between chains was checked using the Brooks-Gelman-Rubin diagnostic and trace plots. There were no closed loops in the evidence networks; thus, there was no reason for the analysis of consistency.

The NMA was conducted using fixed- and random-effect models with deviance information criterion (DIC) as the indicator of model fit to clinical data. The fixed-effect model was preferred; however, the random-effect model was considered relevant when associated with DIC value lower by ≥5 points [27]. The results are presented as HR together with corresponding 95% credible intervals (95% CI). Ranking probabilities of all treatments used the surface under the cumulative ranking area (SUCRA).

### 3. Results

#### 3.1. SLR Results

Overall, 14 RCTs were identified, including a small, phase II study (RIVAL PAD [28]), which did not report any events relevant for this analysis and thus was finally excluded from the NMA. Therefore, a total of 13 RCTs were considered relevant for inclusion in the NMA (Supplementary Table 1). Of those, 8 RCTs (VOYAGER PAD [14], BOA [17], CASPAR [19], Johnson 2002&2004 [23], Cassar 2005 [20], Li 2013 [29], MIRROR [24], and Liang 2012 [30]) recruited patients following peripheral revascularization procedures of the lower extremities. Three studies (BOA [17], CASPAR [19], and Johnson 2002&2004 [23]) assessed patients after recent surgical procedures, four (Cassar 2005 [20], Li 2013 [29], MIRROR [24], and Liang 2012 [30]) recruited participants who have undergone endovascular procedures, and one (VOYAGER PAD) recruited a large sample representative for patients who have undergone either surgical or endovascular procedures. The remaining 5 studies (CAPRIE [18], COMPASS [16], CHARISMA [21], Eikelboom 2005 [22], and WAVE [25]) enrolled patients with a diagnosis of PAD regardless of previous revascularization (Table 2). Figure 1 shows a distribution of clinical trials according to the history and type of revascularization.

Input data for the NMA is presented in Supplementary Tables 1–8. Identified studies differed in terms of

### Table 1: Inclusion criteria for the systematic literature review according to PICOS methodology.

| PICOS | Inclusion criteria |
|-------|-------------------|
| Population | Adults (≥18 years) with acute symptomatic PAD |
| Intervention/comparators | RIV+ASA±CLO |
| | ASA |
| | CLO |
| | CLO+ASA |
| | VKA monotherapy |
| | VKA±(ASA or CLO) |
| Efficacy including the following: | All-cause death |
| Hospitalization for a coronary or peripheral cause (either lower limb) of a thrombotic nature |
| Safety including the following: | Bleeding (major, minor, requiring medical attention, GI, intracranial, and fatal) |
| | AEs (severe, treatment-emergent) |
| | Haemorrhagic stroke |
| | Thrombotic thrombocytopenic purpura |
| Study type: | RCTs |
| All languages |

AE: adverse event; ALI: acute limb ischemia; ASA: aspirin; CLO: clopidogrel; CV: cardiovascular; IS: ischemic stroke; MI: myocardial infarction; PAD: peripheral artery disease; RCT: randomised controlled trial; VKA: vitamin K antagonists.
### Table 2: Characteristics of eligible studies on PAD patients meeting inclusion criteria for NMA.

| Trial name | Treatment | Reference | Sample | Patients after revascularization | Design | Follow-up (months) |
|------------|-----------|-----------|--------|----------------------------------|--------|-------------------|
| **PAD after revascularization: surgical and endovascular** |
| VOYAGER PAD (2020) [14] | RIV 2.5 mg bid+ASA (100 mg) | ASA (100 mg) | 6564 | 100% (recent)* | Double blind | Median: 28 |
| **PAD after revascularization: surgical** |
| BOA (2000) [17] | Phenprocoumon/Acenocoumarol (INR 3.0-4.5) | ASA (80 mg) | 2650 | | Open label | Mean: 21 |
| CASPAR (2010) [19] | CLO+ASA (75-100 mg) | ASA (75-100 mg) | 851 | 100% (recent)* | Double blind | Median: 11.9 |
| Johnson 2002/2004 [23] | Warfarin (INR 1.4-2.8)+ASA (325 mg) | ASA (325 mg) | 831 | | Open label | Mean: 36.6 |
| **PAD after revascularization: endovascular** |
| Cassar 2005 [20] | CLO+ASA (75 mg) | ASA (75 mg) | 132 | | Double blind | 1 |
| Li 2013 [29] | CLO+warfarin (INR 1.8-2.5) | CLO | 88 | 100% (recent)* | Open label | ≤12 |
| MIRROR (2012) [24] | CLO+ASA (100 mg) | ASA (100 mg) | 80 | | Double blind | 6 |
| Liang 2012 [30] | CLO+warfarin (INR 1.8-2.5) | CLO | 56 | | Open label | ≤12 |

**Chronic PAD patients**

| Trial name | Treatment | Reference | Sample | Follow-up |
|------------|-----------|-----------|--------|-----------|
| CAPRIE (1996) [18] | CLO+placebo | ASA (325 mg) | 19,185 (PAD: 6452) | Not reported | Double blind | Mean: 22.9 |
| COMPASS (2017) [16] | RIV (2.5 mg bid)+ASA (100 mg) | ASA (100 mg) | 27,395 (PAD: 7470) | | Double blind | Mean: 23 |
| CHARISMA (2006) [21] | CLO+ASA (75-162 mg) | ASA (75-162 mg) | 15,603 (PAD: 3096) | | Double blind | Median: 28 |
| Eikelboom (2005) [22] | CLO+ASA (100 mg) | ASA (100 mg) | 36 | | Double blind | 3 weeks |
| WAVE (2007) [25] | VKA (INR 2.0-3.0)+ASA (81-325 mg) | ASA (81-325 mg) | 2161 | Not reported | Open label | Mean: 35 |

AE: adverse event; ALI: acute limb ischemia; ASA: aspirin; bid: twice a day; CLO: clopidogrel; CV: cardiovascular; INR: international normalised ratio; IS: ischemic stroke; MI: myocardial infarction; NMA: network meta-analysis; PAD: peripheral artery disease; pt-yrs: patient-years; RCT: randomised controlled trial; VKA: vitamin K antagonists; *treatment was initiated soon after revascularization, not later than 10 days following the procedure.

**Figure 1: Distribution of clinical trials according to the history and type of revascularization.**

- **PAD** 13 RCTs
- **Chronic PAD** 5 RCTs: WASP, CAPRIE, COMPASS, CHARISMA, Eikelboom 2005
- **Surgical revascularisation** 4 RCTs: VOYAGER PAD, BOA, CASPAR, Johnson 2002/4
- **Endovascular revascularisation** 5 RCTs: VOYAGER PAD, CASSAR, Li 2013, MIRROR, Liang 2012
methodological quality, of population characteristics, of procedure types, of follow-up duration, of ASA doses, of history of previous revascularization procedure, and of concomitant CAD and differed regarding major bleeding definition (Supplementary Table 7) and additional treatments contributing to between-trial heterogeneity (Table 2). Moreover, in the light of the rapid development of technologies for endovascular revascularization, all the identified studies assessing P2Y12 receptor antagonist in this group of patients, which were published between 2005 and 2013, may not be representative for the contemporary procedures.

3.1.1. Risk of Bias. The risk of bias was evaluated for all included trials and summarised in Supplementary Table 1. There was no evidence for the risk of bias arising from the randomisation, although Li 2013 did not disclose all necessary details of the randomisation process. All trials comparing different antiplatelet regimens were conducted in a double-blinded fashion, while studies assessing anticoagulation were open label, which is justified given the need for close monitoring of INR in patients receiving VKA. Baseline characteristics were generally well balanced between the study groups; in some studies, there were differences however with no statistically significant interaction with the reported results. There was a higher proportion of patients with a history of coronary artery disease and/or cerebrovascular disease in the CLO treatment arm in the CASPAR trial and a higher proportion of patients with coronary artery disease in the antiplatelet arm in the WAVE trial.

3.1.2. Population. Eleven out of 13 clinical trials enrolled just patients with lower extremity PAD; however, the protocols of 2 RCTs (COMPASS [16]; WAVE [25]) allowed also the inclusion of patients with carotid artery disease.

As mentioned before, the included trials differed regarding a history of the previous revascularization, type of procedures, etc. Eight out of the 13 RCTs were designed to assess therapeutic effects following recent peripheral revascularization. They recruited patients who recently underwent revascularization using either surgical (4 RCTs: VOYAGER PAD [14], BOA, CASPAR [19], and Johnson 2002&2004 [23]) or endovascular procedures (5 RCTs: VOYAGER PAD [14], CASPAR, Li 2013 [29], MIRROR [24], and Liang 2012 [30]) or hybrid procedure (VOYAGER). Studies just including PAD patients after a recent endovascular revascularization were small, with the number of recruited patients ranging from 56 to 132. The VOYAGER PAD trial [14] assessed RIV plus ASA in patients after surgical and/or endovascular procedures. The randomisation in this trial was stratified by procedure type and CLO use into surgical revascularization and endovascular procedures with or without concomitant CLO; hybrid procedure was considered as endovascular procedure.

Six trials (VOYAGER PAD [14], BOA [17], CASPAR [19], Cassar 2005 [20], MIRROR [24], and Li 2013 [29]) provided the number of days, within which the treatment was initiated after the revascularization. In general, the first dose of the investigated treatment was administered within 10 days after the procedure. In one RCT (Johnson 2002&2004 [23]), the treatment with warfarin was administered as soon as patients tolerated oral fluids. The remaining trial (Li 2012) stated that the treatment was initiated following angioplasty.

The 5 remaining trials (WAVE [25], CAPRIE [18], COMPASS [16], CHARISMA [21], and Eikelboom 2005 [22]) recruited patients with chronic PAD. These trials allowed to include patients with or without a history of peripheral revascularization. Prior procedure was not required for enrolment, and the time since revascularization was quite inconsistent. Three (COMPASS [16], CHARISMA [16], and Eikelboom 2005 [22]) out of these 5 RCTs recruiting patients with chronic PAD reported history of peripheral revascularization with a range of 27% to 58% (Table 2).

3.1.3. Interventions and Comparators. Out of the 5 RCTs (BOA [17], Johnson 2002&2004 [23], Li 2013 [29], and Liang 2012 [30]) assessing VKA-based regimens in 2 RCTs (BOA [17]; WAVE [25]), the target INR was 2.0–3.0 and 3.0 to 4.5, respectively. In 11 RCTs (BOA [17], CAPRIE [18], CASPAR [19], Cassar 2005 [20], CHARISMA [21], COMPASS [16], Eikelboom 2005 [22], Johnson 2002&2004 [23], MIRROR [24], VOYAGER PAD [14], and WAVE [25]), patients allocated to the reference arm received either ASA monotherapy and/or ASA combined with other treatments. There was between-trial heterogeneity regarding ASA doses. A high ASA daily dose (325 mg) was administered in 2 trials (CAPRIE [18], Johnson 2002&2004 [23]); a broad range of ASA daily doses (81–325 mg) was allowed in the WAVE trial [25]; and low ASA dose (≤100 mg) was administered in the remaining trials.

In the WAVE trial [25], around 7% of participants received concomitant thienopyridines in either group, which further increased the level of heterogeneity associated with the assessed treatments. There was no analysis stratified by clopidogrel use in the WAVE trial that could assess the potential impact of thienopyridine use on the efficacy and safety results. Similarly, patients assigned to endovascular procedures of the VOYAGER PAD trial were stratified according to clopidogrel use (endovascular procedure with or without clopidogrel), but finally, no significant interaction between clopidogrel use and the outcomes was observed, between-trial heterogeneity.

The analysis of heterogeneity revealed noticeable between-trial differences, which could potentially interact with the estimates of the treatment effects and bias the inference based on the results of the NMA. The most important sources of heterogeneity were rooted in population differences, in procedure differences, e.g., different ASA doses and different treatment strategies. Due to the between-trial heterogeneity, two variants of the analysis were chosen.

(1) Base Case. The aim of this analysis was to assess between-treatment differences in efficacy and safety based on RCTs with a high level of homogeneity regarding the target population and assessing treatment regimens administered in accordance with clinical practice guidelines [4]. Therefore, this
analysis was conducted only on studies recruiting patients following recent revascularization, who received treatment regimens administered within the recommended therapeutic doses.

There was limited number of studies meeting the inclusion criteria for the base case analysis; thus, the comparison with some of the predefined comparators including VKA monotherapy, CLO monotherapy, and the combination treatment including CLO plus ASA was not feasible.

(2) Sensitivity Analysis. The aim of this analysis was to allow for the comparison versus comparators not assessed in the base case and analyse the robustness of the comparative results based on relaxed inclusion/exclusion criteria while acknowledging the heterogeneity introduced with that. This analysis was conducted based on the 13 studies included in the NMA.

3.2. Results of the NMA

3.2.1. Base Case Analysis. Fixed-effect models were considered for each comparison based on DIC criterion and considering that in most cases only one study was available for each comparison; therefore, the heterogeneity parameter could not be estimated. A consistency analysis was not conducted as all the networks had star-like shape without closed loops allowing to compare between direct and indirect evidence.

The trials eligible for the base case analysis allowed to form a network of evidence linking RIV plus ASA (VOYAGER PAD) with CLO plus ASA (CASPAR, Cassar 2005, MIRROR) and VKA plus ASA (Johnson 2002&2004) through ASA monotherapy. RIV plus ASA and CLO plus ASA could formally be compared regarding all outcomes of interest except for ALI, which was assessed only in the VOYAGER PAD trial [14]. On the contrary, the Johnson et al.’s trial (Johnson 2002&2004) [23] which compared VKA plus ASA and ASA reported only all-cause death, any stroke, MI, and major bleeding; therefore, the comparison was limited to reported outcomes.

Consistent with the results of the VOYAGER PAD trial [14], this analysis showed that RIV plus ASA compared with ASA monotherapy is associated with a significantly lower risk of unplanned index-limb revascularization for recurrent ischemia. The comparison between RIV plus ASA with DAPT (CLO plus ASA) and warfarin-based regimen did not reveal any significant differences between treatments regarding safety and efficacy outcomes. However, a trend in favour of RIV plus ASA was observed for comparison with VKA plus ASA regarding all-cause deaths (HR = 0.77 [0.57, 1.04]) (Table 3).

3.2.2. Sensitivity Analysis. Additional trials included in the sensitivity analysis allowed for the assessment of relative treatment effects also versus CLO monotherapy and VKA monotherapy, although the former option was only the comparison for CV deaths, IS, any stroke, and the risk of MI.

Consistent with the base case analysis, RIV plus ASA was associated with a lower risk of peripheral revascularization compared with ASA monotherapy (HR = 0.89 [0.81, 0.98]). For the majority of the remaining outcomes, there was no significant difference between RIV plus ASA and ASA except for the risk of major bleeding, which was significantly higher in the RIV plus ASA group (HR = 1.52 [1.17, 1.98]) compared to ASA alone.

The NMA did not reveal significant treatment differences, with the exception for the comparison with VKA plus ASA regarding major bleeding; there was a lower risk associated with RIV plus ASA (HR = 0.54 [0.33, 0.89]).

The inclusion of additional studies enrolling stable population leads to a nonsignificant modification of the relative effects. The results of the CHARISMA trial [21] favoured CLO plus ASA over ASA regarding all-cause death, CV death, and major bleeding; thus, the point estimates for comparison between RIV plus ASA versus CLO plus ASA favoured the latter treatment regarding these outcomes, although all estimates were not significant.

There were no other major differences in the direction and significance of the effect estimates between the base case scenario and the sensitivity analysis, which could modify the inference.

Input data on amputations for the NMAs are presented in Table 4. Input data on other outcomes for the NMAs (Supplementary Tables 1–8), figures presenting networks of evidence for all outcomes (Supplementary Figures 1, 3, 5, 7, 9, 11, 13, and 15), and forest plots (Supplementary Figures 2, 4, 6, 8, 10, 12, 14, and 16) are presented in Supplementary Materials. The results of the base case scenario and sensitivity analysis are shown in Table 3.

4. Discussion

With this NMA, we attempted to summarise existing evidence on efficacy and safety profiles of treatments used in patients with PAD undergoing peripheral revascularization and accounting for the between-trial heterogeneity and large dispersion of the quality of evidence.

The SLR conducted to collect data for the NMA revealed scarcity and serious limitations of available clinical data. We identified only 5 RCTs reporting adequate results that were eligible for the base case analysis and allowed to compare RIV plus ASA only with 2 regimens: CLO plus ASA and VKA plus ASA. Of those, the VOYAGER PAD study was the largest trial enrolling 6564 out of 8449 patients recruited in all studies included for the base case scenario. The study was designed and powered to compare RIV plus ASA versus ASA in a double-blinded fashion regarding clinically relevant outcomes and showed a significant reduction of the primary efficacy endpoint defined as a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. All participants underwent a recent peripheral revascularization prior to a random allocation to treatment groups, which was stratified according to the type of revascularization procedure (endovascular (including hybrid) vs. surgical) and according to clopidogrel use among those who underwent an endovascular procedure [14]. The primary ITT analysis was based on the primary efficacy
| Outcome                        | Base case scenario | Sensitivity analysis |
|-------------------------------|--------------------|---------------------|
|                               | ASA                | CLO+ASA             | VKA+ASA | DIC | ASA | CLO | CLO+ASA | VKA | VKA+ASA | DIC |
| **All-cause death**           |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 1.08 [0.92, 1.27]  | 0.79 [0.42, 1.50]   | 0.77 [0.57, 1.04] | 3.78 | 1.02 | 0.90 [0.90, 1.17] | 1.08 [0.81, 1.42] | 1.00 [0.80, 1.26] | 0.84 [0.66, 1.06] | 1.704 |
| RE                            | 1.08 [0.00, 2.45]  | 0.99 [0.00, 12.41]  | 0.77 [0.00, 1621.02] | 4.49 | 1.01 | 0.54 [1.83] | 1.02 [0.41, 2.58] | 0.99 [0.34, 2.78] | 0.83 [0.35, 1.95] | 1.832 |
| **CV death**                  |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 1.14 [0.93, 1.40]  | 0.77 [0.37, 1.60]   | No data for comparator | 1.17 | 1.04 | 0.87 [1.24] | 1.34 [0.97, 1.84] | 1.04 [0.73, 1.47] | 1.11 [0.83, 1.48] | 1.00 [0.69, 1.46] | 1.685 |
| RE                            | 1.14 [0.00, 582.71] | 0.77 [0.00, 56.17]  | No data for comparator | 1.10 | 1.00 | 0.17 [5.56] | 1.34 [0.97, 1.84] | 1.06 [0.05, 20.50] | 0.96 [0.05, 18.43] | 1.295 |
| **Ischemic stroke**           |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 0.87 [0.63, 1.20]  | 0.30 [0.01, 7.80]   | No data for comparator | 0.77 | 0.77 | 0.31 [1.17] | 0.30 [0.01, 7.80] | 0.77 [0.01, 19.23] | 1.03 [0.02, 100.50] | 1.13 [0.01, 8.35] | 9.004 |
| RE                            | 0.87 [0.00, 484.60] | 0.30 [0.00, 35.71]  | No data for comparator | 0.73 | 0.73 | 0.30 [1.02] | 0.76 [0.01, 19.23] | 1.43 [0.02, 100.50] | 1.13 [0.01, 83.5] | 9.004 |
| **Any stroke**                |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 0.94 [0.70, 1.28]  | 0.92 [0.35, 2.43]   | 0.89 [0.50, 1.61] | 3.54 | 0.80 | 0.62 [1.04] | 0.81 [0.54, 1.21] | 0.97 [0.61, 1.55] | 1.09 [0.66, 1.80] | 0.78 [0.51, 1.19] | 5.093 |
| RE                            | 0.94 [0.00, 508.30] | 0.93 [0.00, 7213.05] | 0.89 [0.00, 6641.02] | 3.54 | 0.76 | 0.30 [1.74] | 0.77 [0.16, 3.36] | 0.90 [0.23, 2.95] | 1.03 [0.21, 4.61] | 0.74 [0.20, 2.44] | 5.814 |
| **Amputation**                |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 0.89 [0.68, 1.16]  | 1.25 [0.76, 2.07]   | No data for comparator | 1.795 | 0.80 | 0.63 [1.02] | 1.13 [0.73, 1.76] | 0.89 [0.62, 1.28] | 1.20 [0.48, 3.05] | 5.918 |
| RE                            | 0.89 [0.01, 89.00] | 1.19 [0.00, 33.20]  | No data for comparator | 3.019 | 0.75 | 0.26 [1.85] | 1.03 [0.25, 3.37] | 0.84 [0.15, 4.12] | 1.13 [0.17, 6.44] | 6.952 |
| **Myocardial infarction**     |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 0.88 [0.70, 1.12]  | 1.09 [0.42, 2.85]   | 0.69 [0.40, 1.19] | 2.976 | 0.84 | 0.69 [1.02] | 1.34 [0.93, 1.92] | 1.29 [0.84, 1.96] | 1.22 [0.73, 2.05] | 0.88 [0.62, 1.25] | 2.441 |
| RE                            | 0.89 [0.00, 475.10] | 1.11 [0.00, 8665.02] | 0.70 [0.00, 4836.02] | 2.998 | 0.83 | 0.40 [1.69] | 1.32 [0.37, 4.59] | 1.24 [0.40, 3.45] | 1.20 [0.33, 4.41] | 0.84 [0.29, 2.25] | 3.948 |
| **Peripheral revascularization** |                 |                     |         |     |     |     |         |     |         |     |
| FE                            | 0.88 [0.79, 0.99]  | 1.04 [0.75, 1.46]   | No data for comparator | 2.510 | 0.89 | 0.81 [0.98] | 1.13 [0.88, 1.45] | 0.94 [0.80, 1.10] | 0.99 [0.63, 1.58] | 2.239 |
| RE                            | 0.88 [0.00, 189.60] | 1.44 [0.00, 1401.00] | No data for comparator | 1.765 | 0.90 | 0.42 [1.95] | 1.17 [0.51, 4.18] | 0.94 [0.25, 3.61] | 1.00 [0.25, 3.98] | -0.605 |
| **Major bleeding**            |                   |                     |         |     |     |     |         |     |         |     |
| FE                            | 1.43 [0.98, 2.11]  | 0.80 [0.25, 2.56]   | 0.61 [0.30, 1.24] | 4.727 | 1.52 | 1.17 [1.98] | 1.40 [0.81, 2.43] | 0.78 [0.51, 1.17] | 0.54 [0.33, 0.89] | 4.053 |
| RE                            | 1.42 [0.00, 752.41] | 0.79 [0.00, 56.27]  | 0.60 [0.00, 4198.05] | 4.760 | 1.52 | 0.67 [3.45] | 1.34 [0.36, 4.14] | 0.77 [0.19, 3.10] | 0.54 [0.16, 1.74] | 5.770 |

ASA: aspirin; CLO: clopidogrel; DIC: deviance information criterion; FE: fixed effect; RE: random effect; VKA: vitamin K antagonists. Note: the risk of ALI was not reported in the comparator trials; therefore, the comparison regarding this outcome was not feasible.
composite endpoint, and several secondary outcomes were tested in a hierarchical order. The principal safety outcome was major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) classification. The results of the VOYAGER PAD trial showed that RIV plus ASA reduced the risk of the primary efficacy outcome by 15% compared with ASA monotherapy (HR = 0.85 [0.76, 0.96]; p = 0.009) with no significant increase of the rate of TIMI major bleeding (HR = 1.43 [0.97, 2.10]; p = 0.07) and a significant increase in ISTH major bleeding events (HR = 1.42 [1.10, 1.84]; p = 0.007).

While the large VOYAGER study provided high-quality results for assessing the clinical effectiveness of RIV plus ASA, the evidence for other therapeutic options in a postrevascularization setting is limited. ASA and ASA plus CLO were compared in patients after endovascular procedures in only 2 RCTs (Cassar 2005 [20]; MIRROR [24]) recruiting 103 and 68 patients, respectively. Both RCTs were designed to assess platelet functions and had inadequate power for the evaluating clinically relevant outcomes. Moreover, both studies were conducted before 2012 and thus may not represent the contemporary endovascular procedures, which evolved in the recent years.

One trial (CASPAR [19]) compared CLO plus ASA versus ASA monotherapy in 851 patients following surgical revascularization. This study did not demonstrate a benefit of CLO plus ASA over ASA regarding the primary endpoint, defined as a composite of index-graft occlusion or revascularization, above-ankle amputation of the affected limb, or death (HR = 0.98 [0.78-1.23]). A post hoc analysis in the subset of patients with prosthetic grafts showed a difference in favour of the CLO plus ASA regimen (HR = 0.65 [0.45-0.95]). Finally, the remaining trial included in the base case compared VKA plus ASA versus ASA in 831 PAD patients after a surgical revascularization. The study was designed to assess graft patency and mortality. The results indicated that a combination of VKA plus ASA is associated with increased mortality (HR = 1.41 [1.09, 1.84]) and elevated risk of major bleeding (p = 0.02) including intracranial bleed, hospitalization for bleeding, an operation for control of bleeding, or a blood transfusion. Neither of the trials identified through an SLR provided clinical evidence for the efficacy of CLO monotherapy in patients following revascularization; thus, the evidence supporting the use in that population is questionable.

This NMA suggests that RIV in combination with ASA is associated with reduced risk of peripheral revascularization compared with ASA monotherapy, but there seems to be no differences between RIV plus ASA and other treatment options. However, such an indirect comparison has major limitation due to the high heterogeneity of the included trials. The sensitivity analysis with broader inclusion criteria, but with an even more increased heterogeneity, came to the same result. With one exception, the inclusion of additional trials led to an increased estimate of the risk of major bleeding in the VKA plus ASA group compared with RIV plus ASA. The results of this NMA were still imprecise since not all studies included in the network were of sufficient quality and power to draw reliable conclusions based on indirect treatment comparison. Included trials were not powered for the assessment of the individual clinical outcomes but were designed to assess either composite outcomes or surrogates. The results of the sensitivity analysis were associated with high uncertainty due to associated-between-trial heterogeneity. Therefore, although this NMA was conducted in accordance with the highest methodological principles, the available clinical evidence is insufficient to draw reliable conclusions regarding the relative effectiveness and safety of the therapies used in patients after revascularization of peripheral arteries.

The main limitations of the identified scientific evidence are the inadequate samples of included trials and the related insufficient statistical power to assess respective clinically relevant outcomes. In addition, this NMA with a star-like evidence network inherited the limitations from the individual pairwise comparisons, which means that the quality of the

| Study          | Treatments  | Event rate n/N (%) | HR [95% CI] | Base case | Analysis | Sensitivity |
|---------------|-------------|---------------------|-------------|-----------|----------|-------------|
| MIRROR [24]   | CLO+ASA     | 6/35 (17.1%)        | 0.94 [0.30, 2.91] | ✓         | ✓        | ✓           |
|               | ASA         | 6/33 (18.2%)        | Reference   |           |          |             |
| CASPAR [19]   | CLO+ASA     | 31/425 (7.3%)       | 0.68 [0.43, 1.08] | ✓         | ✓        | ✓           |
|               | ASA         | 45/426 (10.6%)      | Reference   |           |          |             |
| VOYAGER PAD   | RIV+ASA     | 103/3286 (3.1%)     | 0.89 [0.68, 1.16] | ✓         | ✓        | ✓           |
|               | ASA         | 115/3278 (3.5%)     | Reference   |           |          |             |
| BOA [17]      | VKA         | 100/1326 (7.5%)     | 0.90 [0.69, 1.19] | ✓         | ✓        | ✓           |
|               | ASA         | 110/1324 (8.3%)     | Reference   |           |          |             |
| CHARISMA [21] | CLO+ASA     | 12/1545 (0.8%)      | 0.71 [0.34, 1.48] | ✓         | ✓        | ✓           |
|               | ASA         | 17/1551 (1.1%)      | Reference   |           |          |             |
| COMPASS [16]  | RIV+ASA     | 20/2492 (0.8%)      | 0.53 [0.31, 0.91] | ✓         | ✓        | ✓           |
|               | ASA         | 38/2504 (1.5%)      | Reference   |           |          |             |
| WAVE [25]     | VKA+ASA     | 8/1080 (0.7%)       | 0.67 [0.27, 1.63] | ✓         | ✓        | ✓           |
|               | ASA         | 12/1081 (1.1%)      | Reference   |           |          |             |

✓: study eligible for the analysis; ✗: study ineligible for the analysis. ASA: acetylsalicylic acid; CLO: clopidogrel; RIV: rivaroxaban; VKA: vitamin K antagonist.
comparison between RIV plus ASA and comparators is limited by the quality of evidence for comparators. Thus, small trials on comparators, not always designed to assess clinically relevant outcomes, are insufficient to draw reliable conclusions regarding relative efficacy and safety between the treatments used in clinical practice in this target population. The low power of this analysis and the between-trial heterogeneity with high probability explains the lack of significant differences between treatments assessed within this NMA. The definition of major bleeding was heterogeneous across included studies (Supplementary Table 7), although there was no evidence that the definition of major bleeding events could affect the relative difference between groups expressed with hazard ratios. Moreover, the risk of bleeding is expected to increase with the dose/number of antiplatelet therapies and the intensity of anticoagulation treatments. Since the daily dose of ASA ranged from 75 mg to 325 mg and the target INR also differed across studies assessing anticoagulation, the between-treatment differences regarding the risk of major bleeding should be interpreted with adequate caution. Despite including additional studies, the sensitivity analysis also did not allow a reliable and unequivocal conclusion regarding treatment differences and did not noticeably change the results of the primary analysis.

In summary, the results of this NMA are considered imprecise due to the low power of some of the included trials to assess relevant clinical outcomes and due to the high between-trial heterogeneity. Therefore, although this NMA was conducted in accordance with high methodological principles, no reliable conclusions regarding efficacy and safety of therapies in symptomatic PAD patients after a recent revascularization can be drawn. To assess clinical efficacy and safety of, for example, clopidogrel or other anticoagulant therapies in such a population, well-powered, randomised double-blind clinical studies like the VOYAGER trial are required.

5. Conclusions

There was limited clinical evidence for the therapies used in the treatment of patients with PAD undergoing peripheral revascularization procedures of the lower extremities. Of these, RIV plus ASA was assessed in the largest clinical program on over 11,500 patients with PAD, of which 6564 were enrolled following recent peripheral revascularization. This analysis suggests that RIV in combination with ASA is associated with reduced risk of revascularization compared with ASA monotherapy, but the evidence for comparators was insufficient to improve treatment decisions and highlights the challenge in establishing the magnitude of comparative treatment effects using existing RCT data. Robust evaluation of clinical outcomes may therefore require extending the scope of the evaluation beyond RCT data.

Data Availability

The input data for NMAs used to support the findings of this study are included within the supplementary information file.

Conflicts of Interest

RB, OW, and NH are external experts invited by Bayer AG to participate in the design of this analysis, consult for study selection and interpretation of the outcomes, and review the manuscript. KB and MH are the employees of Bayer Plc and Bayer AG, respectively, who participated in the design, interpretation of the results, and manuscript preparation. PW and EC are the employees of Creativ-Cometa, who designed the analysis, managed the conduct of simulations and outcome reporting, interpreted the results, and actively participated in the preparation of the manuscript.

Acknowledgments

The authors wish to thank the employees of Creativ-Cometa: Małgorzata Biernikiewicz for medical writing support, Justyna Chorząży and Beata Smela for the management and conduct of the SLR, and Katarzyna Jabłońska for the conduct of statistical analyses. This project was initiated and financed by Bayer AG Pharmaceuticals, which commissioned Creativ-Cometa to design and conduct the analysis.

Supplementary Materials

Supplementary Table 1: credibility assessment of trials included in the NMA [1]. Supplementary Table 2: input data for the NMA of the risk of myocardial infarction. Supplementary Table 3: input data for the NMA of the risk of ischemic stroke. Supplementary Table 4: input data for the NMA of the risk of cardiovascular death. Supplementary Table 5: input data for the NMA of the risk of all-cause mortality. Supplementary Table 6: input data for the NMA of the risk of any stroke. Supplementary Table 7: input data for the NMA of the risk of major bleeding. Supplementary Table 8: input data for the NMA of the risk of revascularization. Supplementary Table 9: networks of evidence for the risk of any stroke. Supplementary Table 10: networks of evidence for the risk of myocardial infarction. Supplementary Table 11: networks of evidence for the risk of ischemic stroke. Supplementary Table 12: networks of evidence for the risk of myocardial infarction. Supplementary Table 13: networks of evidence for the risk of all-cause mortality. Supplementary Table 14: networks of evidence for the risk of any stroke. Supplementary Table 15: networks of evidence for the risk of major bleeding.
networks of evidence for the risk of revascularization. Supplementary Figure 16: forest plots comparing RIV plus ASA versus comparators regarding revascularization. (Supplementary Materials)

References

[1] F. G. Fowkes, V. Aboyans, F. J. Fowkes, M. M. McDermott, U. K. A. Sampson, and M. H. Criqui, “Peripheral artery disease: epidemiology and global perspectives,” Nature Reviews Cardiology, vol. 14, no. 3, pp. 156–170, 2017.

[2] S. L. James, D. Abate, K. H. Abate et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017,” Lancet, vol. 392, no. 10159, pp. 1789–1858, 2018.

[3] L. Harris and M. Dryjski, Epidemiology, risk factors, and natural history of peripheral artery disease. UpToDate, 2013.

[4] V. Aboyans, J. B. Ricco, M. E. L. Bartelink et al., “2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS),” Eur Heart J, vol. 39, no. 9, pp. 763–816, 2018.

[5] G. N. B. Levine, E. R. Bates, J. A. Bittl et al., “2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” The Journal of Thoracic and Cardiovascular Surgery, vol. 152, no. 5, pp. 1243–1275, 2016.

[6] L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Mehler, K. A. Harris, and F. G. R. Fowkes, “Inter-society consensus for the management of peripheral arterial disease (TASC II),” J Vasc Surg, vol. 45, no. 1, Supplement S, pp. S5–67, 2007.

[7] W. T. H. Meijer, A. W. Hoes, D. Rutgers, M. L. Bots, A. Hofman, and D. E. Grobbee, “Peripheral arterial disease in the elderly,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 2, pp. 185–192, 1998.

[8] F. W. Alahdab, A. T. Wang, T. A. Elraiyah et al., “A systematic review for the screening for peripheral arterial disease in asymptomatic patients,” Journal of Vascular Surgery, vol. 61, no. 3, pp. 428–53s, 2015.

[9] C. K. M. Choi, Peripheral arterial disease 2017–2026. Cardio-Vascular Resource Group report, 2017.

[10] R. L. Hardman, O. Jazaeri, J. Yi, M. Smith, and R. Gupta, “Overview of classification systems in peripheral artery disease,” Seminars in Interventional Radiology, vol. 31, no. 4, pp. 378–388, 2014.

[11] G. Dhaliwal and D. Mukherjee, “Peripheral arterial disease: epidemiology, natural history, diagnosis and treatment,” International Journal of Angiology, vol. 16, no. 2, pp. 36–44, 2007.

[12] M. C. Bunte, J. A. House, J. A. Spertus, D. J. Cohen, S. P. Marso, and D. M. Safley, “Association between health status and long-term mortality after percutaneous revascularization of peripheral artery disease,” Catheterization and Cardiovascular Interventions, vol. 87, no. 6, pp. 1149–1155, 2016.

[13] C. N. Hess, R. K. Rogers, T. Y. Wang et al., “Major adverse limb events and 1-year outcomes after peripheral artery revascularization,” Journal of the American College of Cardiology, vol. 72, no. 9, pp. 999–1011, 2018.

[14] M. P. Bonaca, R. M. Bauersachs, S. S. Anand et al., “Rivaroxaban in peripheral artery disease after revascularization,” The New England Journal of Medicine, vol. 382, no. 21, pp. 1994–2004, 2020.

[15] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” BMJ, vol. 343, no. oct18 2, p. d5928, 2011.

[16] J. W. Eikelboom, S. J. Connolly, J. Bosch et al., “Rivaroxaban with or without aspirin in stable cardiovascular disease,” The New England Journal of Medicine, vol. 377, no. 14, pp. 1319–1330, 2017.

[17] Dutch Bypass Oral anticoagulants or Aspirin (ROA) Study Group, “Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial,” Lancet, vol. 355, no. 9201, pp. 346–351, 2000.

[18] CAPRIE Steering Committee, “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE),” Lancet, vol. 348, no. 9038, pp. 1329–1339, 1996.

[19] J. J. Belch, J. Dormandy, CASPAR Writing Committee et al., “Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial,” Journal of Vascular Surgery, vol. 52, no. 4, pp. 825–833.e2, 2010.

[20] K. Cassar, I. Ford, M. Greaves, P. Bachoo, and J. Brittenden, “Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty,” The British Journal of Surgery, vol. 92, no. 2, pp. 159–165, 2005.

[21] D. L. Bhatt, K. A. Fox, W. Hacke et al., “Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events,” The New England Journal of Medicine, vol. 354, no. 16, pp. 1706–1717, 2006.

[22] J. W. Eikelboom, G. J. Hankey, J. Thom et al., “Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2649–2655, 2005.

[23] W. C. Johnson and W. O. Williford, “Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study,” Journal of Vascular Surgery, vol. 35, no. 3, pp. 413–421, 2002.

[24] G. Tepe, R. Bantleon, K. Brechtel et al., “Management of peripheral arterial interventions with mono or dual antiplatelet therapy–the MIRROR study: a randomised and double-blinded clinical trial,” European Radiology, vol. 22, no. 9, pp. 1998–2006, 2012.

[25] Warfarin Antiplatelet Vascular Evaluation Trial Investigators, S. Anand, S. Yusuf et al., “Oral anticoagulant and antiplatelet therapy and peripheral arterial disease,” The New England Journal of Medicine, vol. 357, no. 3, pp. 217–227, 2007.

[26] S. Dias, N. J. Welton, A. J. Sutton et al., NICE DSU technical support document 2: a generalised linear modelling framework
for pairwise and network meta-analysis of randomised controlled trials, NICE DSU TSD series 2, NICE DSU TSD series 2, 2016.

[27] D. J. Spiegelhalter, N. G. Best, B. P. Carlin, and A. van der Linde, "Bayesian measures of model complexity and fit," *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, vol. 64, no. 4, pp. 583–639, 2002.

[28] P. Jetty, D. Kubelik, S. Nagpal et al., "Rivaroxaban plus aspirin versus standard dual antiplatelet therapy following angioplasty for lower extremity peripheral arterial disease in patients with critical limb ischemia and claudication (RIVAL-PAD): 12-month results of a randomized trial," *Journal of Vascular Surgery*, vol. 68, no. 3, article e67, 2018.

[29] H. Li, F. Zhang, G. Liang et al., "A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery," *Annals of Vascular Surgery*, vol. 27, no. 5, pp. 627–633, 2013.

[30] G. Z. Liang, F. X. Zhang, X. Y. Luo et al., "A prospective randomized control clinical trial about clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after femoral-popliteal artery angioplasty," *Zhonghua Wai Ke Za Zhi*, vol. 50, no. 8, pp. 704–708, 2012.